| Value | ₹20.00 Cr |
|---|
NSE filing, NSE: AKUMS. Summary written from the filing by ALFA Finder's alert engine.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹722.70
- Market cap
- ₹11,375 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 39.0×Sector 46.1×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 4.50%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Board Meeting Date
Akums Drugs intimated that its Board meeting is scheduled for 2 November 2026 to consider un-audited Q1 and H1 FY27 results. No financial figures or decisions have been announced yet.
Akums Drugs & Pharmaceuticals Legal & Regulatory
Akums Drugs and Pharmaceuticals received a ₹52.75 Crore NPPA demand notice. The company claims no liability, citing an indemnity agreement with its marketer.
- Value
- ₹52.75 Cr
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ended September 30, 2026. The filing notes the removal of two entities from the promoter group.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals received an ESG rating of 65 for FY2025-26 from NSE Sustainability Ratings & Analytics Limited. The rating was assigned voluntarily based on publicly available information.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Limited has cancelled its participation in the Antique Healthcare Investor Conference scheduled for August 25, 2026, due to unavoidable medical reasons.
Akums Drugs & Pharmaceuticals Earnings Call Transcript: Key Takeaways
Akums reported strong Q1FY27 performance with 13.9% revenue growth and 56.1% PAT increase. Results were driven by a robust 18.6% growth in the CDMO segment and improved API pricing.
Other adverse business impact announcements
All →IIFL Capital Services Adverse Business Impact
IIFL Capital Services' subsidiary surrendered its SEBI Investment Adviser registration, effective October 28, 2026. The company states there is no material monetary impact and no penalty.
Ecoboard Industries Adverse Business Impact
Ecoboard suspended its Particle Board division for one year over raw material shortages and non-viability. Venkatraman Krishnamurthi was appointed CEO, while Gottumukkala steps down to MD.
- Execution
- One (1) year temporary suspension
Latteys Industries Adverse Business Impact
Latteys Industries reported a suspected Boss Scam cyber fraud causing an unauthorised ₹0.8 Crore transfer. No recovery yet; financial impact under assessment.
- Value
- ₹0.80 Cr
Intellect Design Arena Adverse Business Impact
Intellect Design disclosed a cyber incident at its Canadian subsidiary where fake payment instructions were sent to a customer. No funds left the Company's bank accounts and operations are unaffected.
Gulf Oil Lubricants India Adverse Business Impact
Gulf Oil Lubricants reported a fire at its Gujarat warehouse on October 27, 2026. No injuries were reported, and the stock is insured while damage is assessed.
Banswara Syntex Adverse Business Impact
Banswara Syntex reported a fire at its Banswara unit on 27 October 2026, with no casualties. Damage is being assessed and insurance claims are being filed.